Calverley, Peter
Rogliani, Paola
Papi, Alberto
Funding for this research was provided by:
Università degli Studi di Ferrara
Article History
Accepted: 13 November 2020
First Online: 16 December 2020
Declarations
:
: Not applicable
: Peter Calverley has received consulting and personal fees from AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline, Regeneron Sanofi, Recipharm, Philips Medical and Zambon Company SpA, who sponsored this analysis. Paola Rogliani participated as a lecturer, speaker, and advisor for Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. Her department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici. Alberto Papi reports grants, personal fees, and/or reimbursement of travel expenses from AstraZeneca, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mundipharma, Novartis, Teva, Sanofi, and Zambon.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the review conception and design, and revised and commented on all versions of the manuscript. All authors read and approved the final manuscript.